Multiply Labs
Integrator / OEM · US
Robotic biomanufacturing infrastructure: closed, automated workcells that make cell and gene therapies at scale.
Multiply Labs builds robotic biomanufacturing infrastructure: closed, automated workcells that run cell and gene therapy and advanced biologic production with robotic arms instead of manual cleanroom labour. The system integrates third-party instruments (Thermo Fisher, Cytiva, Charles River, Wilson Wolf, GenScript) with Universal Robots arms, orchestrated by software on NVIDIA tooling, and captures process data automatically for traceability. It targets the three failures of the current stack: throughput, cost per dose, and sterility or variability risk from manual handling. Announced collaborations cover AstraZeneca on cell-therapy automation, Legend Biotech and Kyverna Therapeutics. Founded in 2016 out of Y Combinator by MIT-linked founders, it has raised over $100M, including a $75M Series B led by NantWorks.
Research mapping
Physical AI / Manufacturing, EMS & Industrial Automation (L4) / Integrator / OEM
Evidence boundary
Original analysis and independent corroboration remain under development. Commercial scale and durable technical advantage remain under review.
What makes it defensible
A validated closed robotic workcell that both instrument makers and pharma plug into; the integration and sterility qualification is the hard part, not the arm.
Position in the stack: Sits between instrument vendors and pharma manufacturing, owning the automation and qualification layer for therapies that cannot be made at scale manually.
Who buys it
Founding team
Fred Parietti — Co-founder & CEO — MIT researcher in mechanical engineering; co-founded Multiply Labs in 2016 through Y Combinator
Alice Melocchi — Co-founder & CSO — Pharmaceutical scientist and MIT-affiliated researcher; co-founder leading biological process science
SourceFinancing detail
- Last round
- $75M Series B (Oct 2026)
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
No sourced relationships mapped yet.
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.